April 22, 2015

Following Perrigo's rejection of a Mylan offer, Teva moves forward with its proposed acquistion of Mylan. 

April 21, 2015

Teva Pharmaceutical on Tuesday made a move for Mylan in a $40 billion deal barring Mylan's proposed acquisition of Perrigo. 

March 31, 2015

Teva Pharmaceutical Industries announced the launch of generic Exforge (amlodipine and valsartan) tablets, which are indicated for the treatment of hypertension. 

 

March 30, 2015

Teva Pharmaceutical Industries and Auspex Pharmaceuticals announced an agreement under which Teva will acquire Auspex in a deal valued at $3.2 billion.

March 24, 2015

Teva Pharmaceutical Industries on Monday announced that Timothy Wright will be heading business development, strategy and innovation for the company, effective April 13. 

March 10, 2015

ANI Pharmaceuticals acquired the approved abbreviated new drug application for flecainide acetate tablets USP in 50-mg, 100-mg and 150-mg dosage strengths.

March 10, 2015

Teva Pharmaceuticals will sell its Sellersville, Penn., facility to G&W Labs. According to Teva, the move supports its mission of streamlining operations by reducing excess manufacturing capacity.

February 17, 2015

Teva Pharmaceuticals on Tuesday announced the launch of generic versions of Lovenox (enoxaparin sodium injection) as well as generic Zyvox (linezolid) injection. 

 

February 3, 2015

Teva Pharmaceuticals on Tuesday announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in 10-mg dosage strength.

January 27, 2015

Teva Pharmaceutical Industries announced that the Food and Drug Administration approved the company’s first generic Nexium delayed-release tablets in the United States.

January 20, 2015

Teva Pharmaceutical on Tuesday announced the U.S. Supreme Court’s decision in Teva Pharmaceuticals USA vs. Sandoz et al. that reversed the Federal Circuit Court’s judgment of invalidity of Teva’s ‘808 patent for Copaxone (glatiramer acetate injection) 20 mg/mL.

January 9, 2015

Teva Pharmaceuticals on Friday announced the launch of linezolid injection, the generic equvialent to Zyvox injection from C.P. Pharmaceuticals.

January 7, 2015

Teva Pharmaceutical on Tuesday announced the Food and Drug Administration approved the launch of the company's valsartan tablets, the generic version of Diovan tablets from Novartis. 

 

December 23, 2014

Teva Pharmaceutical today announced that the Food and Drug Administration has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the approval of this additional administration option, physicians will soon have the flexibility to prescribe Granix for either in-office or at home use.

December 19, 2014

Teva Pharmaceutical announced that the Food and Drug Administration approved QNasl (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis in children ages 4 years to 11 years.

December 11, 2014

Teva Pharmaceuticals on Thursday announced the availability of levalbuterol inhalation solution, USP (concentrate), a generic equivalent to Xopenex inhalation solution concentrate. 

December 10, 2014

Teva Pharmaceutical Industries on Wednesday announced the launch of generic Celebrex (celecoxib) capsules in the United States. The company is offering the capsules in 50-,100-, 200- and 400-mg dosage strengths. 

 

December 9, 2014

Teva Canada, a subsidiary of Teva Pharmaceutical Industries, announced Tuesday that Health Canada has approved its application for the generic version of PrTarceva. 

December 2, 2014

Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII.

December 1, 2014

Teva Pharmaceutical on Monday announced the launch of a generic version of Exforge HCT (amlodipine, valsartan, hydrochlorothiazide) tablets in the United States. 

November 18, 2014

Teva Canada Limited, a subsidiary of Teva Pharmaceutical Industries, on Tuesday announced that Health Canada has approved its application for PrTeva-Celecoxib, the generic equivalent of PrCelebrex.

November 11, 2014

Teva Pharmaceuticals announced the introduction of dexmethylphenidate hydrochloride extended-release capsules, CII, in a 5-mg strength.

October 15, 2014

The U.S. Supreme Court on Wednesday heard arguments from Teva Pharmaceutical Industries in defense of the patent protecting its $4 billion multiple sclerosis drug Copaxone, according to a Reuters report. 

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.